Skip to main content
SpringerLink
Log in

Betablocker nach Infarkt: Dauertherapie für alle! Oder doch nicht?

Beta blockers after myocardial infarction: forever or not forever—That is the question?

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177

    Article  Google Scholar 

  2. Kim J, Kang D, Park H, Kang M, Park TK, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Guallar E, Cho J, Hahn JY (2020) Long-term β‑blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J 41(37):3521–3529

    Article  Google Scholar 

  3. Neumann A, Maura G, Weill A, Alla F, Danchin N (2018) Clinical events after discontinuation of β‑blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French Healthcare databases. Circ Cardiovasc Qual Outcomes 11(4):e4356

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardioangiologisches Centrum Bethanien (CCB), Frankfurt, Deutschland

    Holger Eggebrecht

Authors
  1. Holger Eggebrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Eggebrecht.

Ethics declarations

Interessenkonflikt

H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eggebrecht, H. Betablocker nach Infarkt: Dauertherapie für alle! Oder doch nicht?. Kardiologe 15, 315–316 (2021). https://doi.org/10.1007/s12181-021-00481-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-021-00481-w

Search

Navigation